Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide plus rituximab maintenance and cytarabine-containing induction in older mantle cell lymphoma
NL-OMON54774Phase 3Completed
- Sponsor
- LYSARC
- Start
- Dec 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lenalidomide, rituximab, cyclophosphamide, doxorubicin, vincristine and 3 more in mantle cell lymphoma (MCL) (4 arms), sponsored by LYSARC. Primary endpoint: Progression-free survival from maintenance randomization. Started Dec 2015; status: completed.
02
Drugs
lenalidomiderituximabcyclophosphamidedoxorubicinvincristine
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NL-OMON54774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54774.